Status:
COMPLETED
Anlotinib Retrospective Study for Esophageal Cancer
Lead Sponsor:
Feng Wang
Conditions:
Esophageal Neoplasms
Eligibility:
All Genders
Brief Summary
The efficacy of anlotinib in the treatment of esophageal cancer has been confirmed. The purpose of this study was to retrospectively observe the efficacy and safety of anlotinib in the first and secon...
Eligibility Criteria
Inclusion
- Esophageal cancer diagnosed pathologically or clinically
- Patients who use anlotinib alone, or combined with chemoradiotherapy, or plus PD-1 inhibitors in first-line or second-line treatment
Exclusion
- None
Key Trial Info
Start Date :
January 1 2019
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
March 1 2022
Estimated Enrollment :
300 Patients enrolled
Trial Details
Trial ID
NCT05303740
Start Date
January 1 2019
End Date
March 1 2022
Last Update
March 31 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
The First Affiliated Hospital of Zhengzhou University
Zhengzhou, Henan, China, 450000